Pentoxifylline in the treatment of radiation-related soft tissue injury: Preliminary observations

Laryngoscope

Volumn 107, Issue 3, 1997, Pages 391-395

  Futran, Neal D ^a,b   Trotti, Andrea ^a   Gwede, Clement ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; METHYLXANTHINE DERIVATIVE; PENTOXIFYLLINE;

ARTICLE; BLOOD VISCOSITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; FIBROSIS; HEAD AND NECK CANCER; HUMAN; PAIN; PRIORITY JOURNAL; RADIATION INJURY; SOFT TISSUE INJURY; TISSUE NECROSIS; TISSUE OXYGENATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANALGESICS; ANTI-BACTERIAL AGENTS; ATROPHY; DEBRIDEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBROSIS; HEAD AND NECK NEOPLASMS; HEMORHEOLOGY; HUMANS; MALE; MIDDLE AGED; MOUTH DISEASES; MOUTH MUCOSA; NECROSIS; ORAL ULCER; OSTEORADIONECROSIS; OXYGEN CONSUMPTION; PAIN; PENTOXIFYLLINE; PHYSICAL THERAPY MODALITIES; RADIATION INJURIES; REMISSION INDUCTION; SOFT TISSUE INJURIES; VASODILATOR AGENTS; WOUND HEALING;

EID: 0030948870     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199703000-00022     Document Type: Article

References (22)

1. Cox JD, Pajak TF, Marcial VA, et al. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: Preliminary report of radiation therapy oncology group protocol 83-13. Int J Radiat Oncol Biol Phys. 1990;18:515-521.
2. Perego MA, Sergio G, Artale F, Giunti P, Danese C. Haemorpheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease. Curr Med Res Opin. 1986;10:135-138.
3. Fajardo LF, Stewart JR. Capillary injury preceding radiation-induced myocardial fibrosis. Radiology. 1971;101:429-433.
4. Gastpar H. Platelet-cancer cell interaction in metastasis formation: a possible therapeutic approach to metastasis prophylaxis. J Med. 1977;8:103-114.
5. Luke DR, O'Donell MP, Keane Wf, Matzke GR. Lack of pharmacodynamic interaction between pentoxifylline and warfarin in the rat. Res Commun Chem Pathol Pharmacol. 1986;54:65-72.
6. Muller R, Schroer R. Cerebrovascular circulatory disorders: new aspects of pathophysiology and therapy. J Med. 1979;10:347-364.
7. King Ge, Scheetz J, Jacob RF, Martin JW. Electrotherapy and hyperbaric oxygen: Promising treatments for postradiation complications. J Prosthet Dent. 1989;62(3):331-334.
8. Hart GH, Mainous EG. The treatment of radiation necrosis with hyperbaric oxygen. Cancer. 1976;37:2580-2585.
9. Dion MW, Hussey DH, Doornbos JF, Vigliotti AP, Wen BC, Anderson B. Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis. Int J Radiat Oncol Biol Phys. 1990;401-407.
10. Hussey Dh, Friedland JL. Second report of a pilot study of pentoxifylline in the treatment of late radiation necrosis. Proceedings of the Workshop on Pentoxifylline Leukocyte Cytokines: Potential Therapeutic Uses. Scottsdale, Arizona; March 8-10, 1991.
11. Hopewell, JW. The importance of vascular damage in the development of late radiation effects in normal tissues. In: Meyn RE, Withers HR, eds. Radiation biology in cancer research. New York: Raven, 1980:449-459.
12. Movat HZ, Cubulsky MI, Colditz IG, Chan KW, Cinarello CA. Acute inflammation in gram-negative infection: Endotoxin, interleukin-1, tumor necrosis factor, and neutrophils. Fed Proc. 1987;46:97-104.
13. Sullivan GW, Carper HT, Novich WJ Jr., Mandell GL. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun. 1988;56:1722-1729.
14. Poggesi L, Scarti L, Boddi M. Masotti G, Serneri GG. Pentoxifylline treatment in patients with occlusive peripheral vascular disease. Angiology. 1985;6:637-638.
15. Singzinger H, Cromwell M, Firbas W. Long-lasting depression of rabbit aortic prostacyclin formation by single-dose radiation. Radiat Res. 1984;97:533-536.
16. Ambrus JL, Ambrus CM, Gastpar H. Studies on platelet aggregation with pentoxifylline: Effect in neoplastic disorders and other new indications. J Med. 1979;10:339-345.
17. Gorog P, Kovacs IB. Prostacyclin is a more potent stimulator of thrombolysis than inhibitor of haemostasis. Haemostasis. 1986;16:337-345.
18. Singzinger H, Firbas W. radiation depresses prostacyclin generation upon stimulation with the platelet-derived growth factor. Br J Radiol. 1985;58:1023-1026.
19. Beerman B, Ings R, Mansby J, Chamberlain J, McDonald A. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther. 1985;37:25-28.
20. McMenamin PG. Pentoxifylline in head and neck cancer patients. In: Hakim J, Mandell GL, Novich WJ Jr, eds. Proceedings of the Workshop on Pentoxifylline and Analogs Effects on Leukocyte Function. St. Paul-De-Vence, France, November 10-11, 1989.
21. Takayanagi S, Ogawa Y. Effects of pentoxifylline on flap survival. Plast Reconstr Surg. 1980;65:763-767.
22. Delanian S, Baillet F, Huart J, et al. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother Oncol. 1994;32:12-20.